Clinical Effects and Safety of Intra-Arterial Infusion Chemotherapy with Lipiodol versus Intra-Arterial Infusion Chemotherapy Alone for Treatment of Advanced Hepatocellular Carcinoma

被引:0
作者
Kim, Su Ho [1 ]
Oh, Jung Suk [1 ]
Jeon, Chang Ho [2 ]
Chun, Ho Jong [1 ]
Choi, Byung Gil [1 ]
机构
[1] Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Radiol, Seoul, South Korea
[2] Catholic Univ Korea, Eunpyeong St Marys Hosp, Coll Med, Radiol, Seoul, South Korea
关键词
Hepatocellular carcinoma; Intra-arterial infusion chemotherapy; Lipiodol; ARTERIAL INFUSION; TUMOR THROMBOSIS; NATURAL-HISTORY; CISPLATIN; 5-FLUOROURACIL; SUSPENSION; SORAFENIB; THERAPY;
D O I
10.1159/000541114
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: This study aimed to assess the effectiveness and safety of hepatic arterial infusion chemotherapy (HAIC) in 2 groups of patients: those who receive lipiodol (referred to as the lipiodol group) and those who do not receive lipiodol (referred to as the control group). Methods: From January 2016 through December 2023, 85 patients with advanced hepatocellular carcinoma were enrolled in this retrospective study. In total, 40 patients received HAIC with lipiodol, while 45 patients were given HAIC without lipiodol. The modified response evaluation criteria for solid tumors were used to evaluate the tumor response, which was assessed through an imaging study. The two groups were compared regarding their overall survival (OS), progression-free survival (PFS), and safety. Results: The outcomes between the lipiodol group and control group demonstrated no significant difference: the objective response rates (p = 0.066) were 32.5% and 15.6%; the disease control rates (p = 0.556) were 67.5% and 73.3%; the median OS times (p = 0.339) were 224 days and 398 days; the median PFS (p = 0.334) times were 191 days and 286 days in the lipiodol group and the control group, respectively. Adverse events also showed no significant difference between the two groups: elevation of total bilirubin (p = 0.834) rates were 40.0% and 37.8%; elevation of alanine aminotransferase (p = 0.191) percentages were 35.0% and 22.2%; and elevation of aspartate aminotransferase values (p = 0.058) were 65.0% and 44.4% in the lipiodol group and the control group, respectively. Conclusions: HAIC without lipiodol was non-inferior to HAIC with lipiodol in the clinical outcome.
引用
收藏
页码:290 / 297
页数:8
相关论文
共 25 条
[1]   Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis - Analysis of 48 cases [J].
Ando, E ;
Tanaka, M ;
Yamashita, F ;
Kuromatsu, R ;
Yutani, S ;
Fukumori, K ;
Sumie, S ;
Yano, Y ;
Okuda, K ;
Sata, M .
CANCER, 2002, 95 (03) :588-595
[2]   Hepatic Arterial Infusion Chemotherapy Followed by Lipiodol Infusion for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Single-Center Experience [J].
Chen, Kuan-Ting ;
Tsai, Kun-Feng ;
Leung, Henry W. C. ;
Chan, Agnes L. F. ;
Wang, Shyh-Yau ;
Liang, Huei-Lung ;
Tang, Sheng-Yeh ;
Chou, Chu-Kuang ;
Chen, Hsin-Yu ;
Chan, Shan-Ho ;
Li, Ming-Feng .
MEDICINA-LITHUANIA, 2021, 57 (08)
[3]   Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial [J].
Cheng, Ann-Lii ;
Kang, Yoon-Koo ;
Chen, Zhendong ;
Tsao, Chao-Jung ;
Qin, Shukui ;
Kim, Jun Suk ;
Luo, Rongcheng ;
Feng, Jifeng ;
Ye, Shenglong ;
Yang, Tsai-Sheng ;
Xu, Jianming ;
Sun, Yan ;
Liang, Houjie ;
Liu, Jiwei ;
Wang, Jiejun ;
Tak, Won Young ;
Pan, Hongming ;
Burock, Karin ;
Zou, Jessie ;
Voliotis, Dimitris ;
Guan, Zhongzhen .
LANCET ONCOLOGY, 2009, 10 (01) :25-34
[4]   Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis [J].
Choi, Jong Hwan ;
Chung, Woo Jin ;
Bae, Si Hyun ;
Song, Do Seon ;
Song, Myeong Jun ;
Kim, Young Seok ;
Yim, Hyung Joon ;
Jung, Young Kul ;
Suh, Sang Jun ;
Park, Jun Yong ;
Kim, Do Young ;
Kim, Seung Up ;
Cho, Sung Bum .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (03) :469-478
[5]   Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-α for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis [J].
Eun, Jong Ryul ;
Lee, Heon Ju ;
Moon, Hee Jung ;
Kim, Tae Nyeun ;
Kim, Jae Woon ;
Chang, Jay Chun .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (12) :1477-1486
[6]   Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review [J].
Han, Kichang ;
Kim, Jin Hyoung ;
Ko, Gi-Young ;
Gwon, Dong Il ;
Sung, Kyu-Bo .
WORLD JOURNAL OF GASTROENTEROLOGY, 2016, 22 (01) :407-416
[7]   Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma [J].
Ikeda, Masafumi ;
Maeda, Seishi ;
Ashihara, Hiroshi ;
Nagahama, Hiroyasu ;
Tanaka, Motohiko ;
Sasaki, Yutaka .
JOURNAL OF GASTROENTEROLOGY, 2010, 45 (01) :60-67
[8]  
Jang Byoung Kuk, 2005, Korean J Hepatol, V11, P359
[9]  
Kim Hee Yeon, 2010, Korean J Hepatol, V16, P355, DOI 10.3350/kjhep.2010.16.4.355
[10]   Lipiodol = Ethiodol [J].
Kolbeck, Kenneth J. .
JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2011, 22 (03) :419-420